Surgalign Holdings stock (US87936R1068): Xtant Medical closes acquisition and prepares to delist shares

Surgalign Holdings shares continue to trade on Nasdaq after Xtant Medical completed its asset acquisition in 2023, while the company now moves toward a planned Chapter 11 liquidation and delisting in the United States.

Surgalign Holdings stock remains quoted on Nasdaq in the United States even as the underlying business has been sold and the company is progressing toward a court-supervised liquidation process that is expected to end in a delisting of the shares.

According to a 06/21/2023 press release filed with the U.S. Securities and Exchange Commission, Surgalign Holdings announced that it had agreed to sell substantially all of its global hardware and biomaterials assets, including key spinal implant product lines, to Xtant Medical for a purchase price of USD 5 million in cash plus the assumption of certain liabilities as part of a Chapter 11 restructuring.SEC filing as of 06/21/2023

In parallel with the transaction announcement, Surgalign Holdings stated in a separate 06/20/2023 communication that it had voluntarily filed for Chapter 11 protection in the U.S. Bankruptcy Court for the Southern District of Texas, indicating that the proceeds from the sale to Xtant Medical and a related sale of the digital health business would be used to repay creditors and wind down operations.Surgalign IR as of 06/20/2023

On Nasdaq, where Surgalign trades under the ticker SRGA, the company has seen trading volumes shrink following the asset sale and bankruptcy disclosure, with recent quotes reflecting the market's focus on residual claim value rather than an ongoing operating business, according to Nasdaq data as of 05/28/2026.

The stock traded at a low single-digit cent price on 05/28/2026 on Nasdaq, underscoring that investors are now pricing primarily the expected recovery, if any, from the liquidation process rather than growth prospects for a going concern, based on Nasdaq price information as of 05/28/2026.

As of: 05/28/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: SRGA
• Sector/industry: Medical technology / spine devices (pre-liquidation)
• Headquarters/country: Deerfield, United States
• Core markets: United States and selected international markets in spine surgery solutions (operations largely sold as of mid-2023)
• Key revenue drivers: Historically spinal implant hardware, biomaterials and related products prior to asset sale
• Home exchange/listing venue: Nasdaq (SRGA)
• Trading currency: USD

Surgalign Holdings: core business model

Before entering Chapter 11 and divesting its core assets in 2023, Surgalign Holdings focused on spinal implants and orthobiologic solutions for surgeons, generating its revenue largely from sales of hardware and biomaterials used in spine procedures.

Industry trends and competitive position

The spine and orthobiologics industry in which Surgalign previously operated is characterized by steady demand from aging populations, expanding procedural volumes in degenerative and deformity spine surgery, and continuous product innovation from both large diversified medtech groups and smaller focused players. According to an industry report from 2024, the global spinal implants and surgical devices market was projected to grow at a mid-single-digit compound annual rate through the second half of the decade, driven by higher case volumes, increased adoption of minimally invasive techniques and the introduction of next-generation biomaterials in the United States and other key regions.

Within this context, Surgalign had been a smaller competitor against larger spine device and orthobiologics manufacturers, typically relying on a limited portfolio and partner distribution to reach hospitals and surgical centers. The sale of the Surgalign hardware and biomaterials portfolio to Xtant Medical in 2023 effectively strengthened Xtant Medical's position in this market by adding additional product lines and customer relationships, while leaving Surgalign to focus on its restructuring obligations and the wind-down of its remaining activities.Xtant Medical press release as of 06/21/2023

Conclusion

Surgalign Holdings has effectively transitioned from an operating spine device company to a restructuring vehicle following the sale of its core assets to Xtant Medical and its Chapter 11 filing in the United States, leaving the remaining equity focused on potential liquidation outcomes. The broader spine and orthobiologics sector continues to grow moderately, but the asset transfer means that any future upside from these market trends is expected to accrue to the acquiring players rather than to Surgalign itself. For holders of the Nasdaq-listed shares, the key variables now center on the progress of the U.S. court process, distributions to creditors and residual recovery prospects for equity rather than on new product launches or operational milestones.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.